Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
64.41
-3.55 (-5.22%)
Mar 31, 2025, 10:01 AM EDT - Market open
Arcellx Employees
Arcellx had 163 employees as of December 31, 2024. The number of employees increased by 33 or 25.38% compared to the previous year.
Employees
163
Change (1Y)
33
Growth (1Y)
25.38%
Revenue / Employee
$662,184
Profits / Employee
-$658,577
Market Cap
3.54B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 163 | 33 | 25.38% |
| Dec 31, 2023 | 130 | 32 | 32.65% |
| Dec 31, 2022 | 98 | 20 | 25.64% |
| Dec 31, 2021 | 78 | 47 | 151.61% |
| Dec 31, 2019 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACLX News
- 10 days ago - Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors - Business Wire
- 13 days ago - Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month - GlobeNewsWire
- 13 days ago - Arcellx Impressive Safety Data Leaves Doubts - Seeking Alpha
- 4 weeks ago - Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights - Business Wire
- 4 weeks ago - Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference - Business Wire
- 4 months ago - Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients - Benzinga
- 4 months ago - Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition - Business Wire
- 5 months ago - Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights - Business Wire